Menu

Experience

Chadwick Mills

    • BioMarin – $720 Million Follow-On Offering 


    • Cooley Advised Jazz Pharmaceuticals on Rule 144A Offering of $575 Million of Exchangeable Senior Notes 


    • BioMarin Pharmaceutical: $720 Million Public Offering of Common Stock 


    • Jazz Pharmaceuticals Acquires Celator for $1.5 Billion 


    • Seattle Genetics: $552 Million Follow-On 


    • Horizon Pharma Acquires Vidara Therapeutics and Enters Five-Year $300 Million Term Loan Facility 


    • Jazz Pharmaceuticals plc Rule 144A Offering of $575 Million of Exchangeable Senior Notes 


    • Jazz Pharmaceuticals – $575 Million Exchangeable Senior Note Offering 


    • Horizon Pharma Acquires Vidara Therapeutics and Enters Five-Year $300 Million Term Loan Facility 


    • Jazz Pharmaceuticals $125 Million Acquisition of ADX-N05 


    • AcelRx Pharmaceuticals in Public Offering 


    • Jazz Pharmaceuticals in $314.4 million Offering 


Contact us

Back to top

© 2020 Cooley LLP and Cooley (UK) LLP. All rights reserved.

Cooley® is a registered service mark of Cooley LLP in the United States and European Union as well as certain other jurisdictions.